Albert D Windhorst

List of Publications by Year
in descending order

263 papers	9,397 citations	44069 48 h-index	54911 84 g-index
280 all docs	280 docs citations	280 times ranked	11677 citing authors

#	Article	IF	Citations
1	Microglia Activation in Recent-Onset Schizophrenia: A Quantitative (R)-[11C]PK11195 Positron Emission Tomography Study. Biological Psychiatry, 2008, 64, 820-822.	1.3	534
2	Î"9-Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum. Neuropsychopharmacology, 2009, 34, 759-766.	5.4	341
3	Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nature Communications, 2018, 9, 4664.	12.8	331
4	Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs. Cancer Cell, 2012, 21, 82-91.	16.8	307
5	Blood–brain barrier P-glycoprotein function in Alzheimer's disease. Brain, 2012, 135, 181-189.	7.6	252
6	Relationship of Cerebrospinal Fluid Markers to ^{11}C-PiB and ^{18}F-FDDNP Binding. Journal of Nuclear Medicine, 2009, 50, 1464-1470.	5.0	162
7	Consensus nomenclature rules for radiopharmaceutical chemistry â€" Setting the record straight. Nuclear Medicine and Biology, 2017, 55, v-xi.	0.6	162
8	Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's and Dementia, 2013, 9, 414-421.	0.8	159
9	Fluorine-18 labelled building blocks for PET tracer synthesis. Chemical Society Reviews, 2017, 46, 4709-4773.	38.1	150
10	Longitudinal Amyloid Imaging Using ^{11}C-PiB: Methodologic Considerations. Journal of Nuclear Medicine, 2013, 54, 1570-1576.	5.0	148
11	Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 990-1000.	6.4	145
12	Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study. Neurobiology of Aging, 2013, 34, 128-136.	3.1	145
13	P-Glycoprotein Function at the Blood–Brain Barrier: Effects of Age and Gender. Molecular Imaging and Biology, 2012, 14, 771-776.	2.6	127
14	Microglial activation in healthy aging. Neurobiology of Aging, 2012, 33, 1067-1072.	3.1	125
15	Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14620-14625.	7.1	121
16	Detection of Alzheimer Pathology In Vivo Using Both ^{11}C-PIB and ^{18}F-FDDNP PET. Journal of Nuclear Medicine, 2009, 50, 191-197.	5.0	119
17	Development of [11C]erlotinib Positron Emission Tomography for *In Vivo* Evaluation of EGF Receptor Mutational Status. Clinical Cancer Research, 2013, 19, 183-193.	7.0	117
18	Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. Brain, 2012, 135, 2115-2125.	7.6	109

#	ARTICLE	IF	CITATIONS
19	Effects of Hepatic Triglyceride Content on Myocardial Metabolism in Type 2 Diabetes. Journal of the American College of Cardiology, 2010, 56, 225-233.	2.8	108
20	(R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nuclear Medicine and Biology, 2003, 30, 747-751.	0.6	106
21	Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs. Clinical Cancer Research, 2021, 27, 189-201.	7.0	106
22	Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood–brain barrier: kinetics and metabolism in the rat. Nuclear Medicine and Biology, 2005, 32, 87-93.	0.6	102
23	Differential effect of *APOE* genotype on amyloid load and glucose metabolism in AD dementia. Neurology, 2013, 80, 359-365.	1.1	99
24	Quantification of [^{18}F]DPA-714 Binding in the Human Brain: Initial Studies in Healthy Controls and Alzheimer'S Disease Patients. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 766-772.	4.3	99
25	TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging. Clinical Cancer Research, 2015, 21, 2984-2992.	7.0	95
26	Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1950-1958.	6.4	92
27	Purinergic receptors P2Y12R and P2X7R: potential targets for PET imaging of microglia phenotypes in multiple sclerosis. Journal of Neuroinflammation, 2017, 14, 259.	7.2	91
28	Evaluation of Tracer Kinetic Models for Quantification of P-Glycoprotein Function using (R)-[11C]Verapamil and PET. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 424-433.	4.3	87
29	PET Imaging of Microglial Activation—Beyond Targeting TSPO. Molecules, 2018, 23, 607.	3.8	85
30	A Universal Procedure for the [^{18}F]Trifluoromethylation of Aryl Iodides and Aryl Boronic Acids with Highly Improved Specific Activity. Angewandte Chemie - International Edition, 2014, 53, 11046-11050.	13.8	84
31	*In Vivo* Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging. Clinical Cancer Research, 2014, 20, 6389-6397.	7.0	81
32	Tariquidar and Elacridar Are Dose-Dependently Transported by P-Glycoprotein and Bcrp at the Blood-Brain Barrier: A Small-Animal Positron Emission Tomography and In Vitro Study. Drug Metabolism and Disposition, 2013, 41, 754-762.	3.3	79
33	Widespread and Prolonged Increase in (*R*)-^{11}C-PK11195 Binding After Traumatic Brain Injury. Journal of Nuclear Medicine, 2011, 52, 1235-1239.	5.0	72
34	Synthesis and initial preclinical evaluation of the P2X$_7$ receptor antagonist [^{11}C]A-740003 as a novel tracer of neuroinflammation. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 509-516.	1.0	70
35	Transition metal mediated synthesis using [^{11}C]CO at low pressure – a simplified method for ^{11}C‑carbonylation. Journal of Labelled Compounds and Radiopharmaceuticals, 2012, 55, 223-228.	1.0	69
36	Development of a Tracer Kinetic Plasma Input Model for (R)-[11C]PK11195 Brain Studies. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 842-851.	4.3	68

#	Article	IF	Citations
37	Phase I Trial of ^{131}I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients. Journal of Nuclear Medicine, 2021, 62, 1097-1105.	5.0	67
38	Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nuclear Medicine and Biology, 2009, 36, 643-649.	0.6	66
39	Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3â€²-fluoro-3â€²-deoxy-thymidine ([18F]FLT) PET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18396-18399.	7.1	65
40	PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET. Drug Discovery Today, 2012, 17, 1175-1187.	6.4	64
41	In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [18F]DPA714 PET. Journal of Neuroinflammation, 2018, 15, 314.	7.2	64
42	Imaging of neuroinflammation in Alzheimer's disease, multiple sclerosis and stroke: Recent developments in positron emission tomography. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 425-441.	3.8	63
43	Test-retest variability of quantitative [11C]PIB studies in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1629-1638.	6.4	62
44	Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography. Clinical Cancer Research, 2013, 19, 4163-4173.	7.0	58
45	Evaluation of the novel folate receptor ligand [18F]fluoro-PEG-folate for macrophage targeting in a rat model of arthritis. Arthritis Research and Therapy, 2013, 15, R37.	3.5	57
46	Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activation. Scientific Reports, 2018, 8, 6580.	3.3	54
47	Quantification of PD-L1 Expression with ^{18}F-BMS-986192 PET/CT in Patients with Advanced-Stage Nonâ€"Small Cell Lung Cancer. Journal of Nuclear Medicine, 2020, 61, 1455-1460.	5.0	54
48	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology, 2014, 82, 1768-1775.	1.1	51
49	A New Highly Reactive and Low Lipophilicity Fluorine-18 Labeled Tetrazine Derivative for Pretargeted PET Imaging. ACS Medicinal Chemistry Letters, 2016, 7, 62-66.	2.8	50
50	Pretargeted PET Imaging of *trans*-Cyclooctene-Modified Porous Silicon Nanoparticles. ACS Omega, 2017, 2, 62-69.	3.5	50
51	Identification of new molecular targets for PET imaging of the microglial anti-inflammatory activation state. Theranostics, 2018, 8, 5400-5418.	10.0	48
52	In vivo tau pathology is associated with synaptic loss and altered synaptic function. Alzheimer's Research and Therapy, 2021, 13, 35.	6.2	47
53	Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. Neurology, 2009, 73, 2079-2085.	1.1	45
54	Reproducibility of quantitative (R)-[11C]verapamil studies. EJNMMI Research, 2012, 2, 1.	2.5	45

#	Article	IF	Citations
55	Feasibility and repeatability of PET with the hypoxia tracer [18F]HX4 in oesophageal and pancreatic cancer. Radiotherapy and Oncology, 2015, 116, 94-99.	0.6	44
56	The P2X7 receptor tracer [11C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 379-389.	6.4	44
57	Monitoring Response to Radiotherapy in Human Squamous Cell Cancer Bearing Nude Mice: Comparison of 2â€²-deoxy-2â€²-[18F]fluoro-d-glucose (FDG) and 3â€²-[18F]fluoro-3â€²-deoxythymidine (FLT). Molecular Imaging and Biology, 2007, 9, 340-347.	2.6	43
58	(R)-[11C]Verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus. BMC Medical Imaging, 2011, 11, 1.	2.7	43
59	First in man study of [18F]fluoro-PEG-folate PET: a novel macrophage imaging technique to visualize rheumatoid arthritis. Scientific Reports, 2020, 10, 1047.	3.3	43
60	Preclinical Targeted Î±- and Î²â€“-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies. Cancers, 2020, 12, 1017.	3.7	43
61	Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 694-707.	6.4	43
62	Quantification of Tau Load Using [18F]AV1451 PET. Molecular Imaging and Biology, 2017, 19, 963-971.	2.6	42
63	Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project. Neurobiology of Aging, 2019, 79, 50-58.	3.1	41
64	[18F]VM4-037 MicroPET Imaging and Biodistribution of Two In Vivo CAIX-Expressing Tumor Models. Molecular Imaging and Biology, 2015, 17, 615-619.	2.6	40
65	Discordant amyloid-Î² PET and CSF biomarkers and its clinical consequences. Alzheimer's Research and Therapy, 2019, 11, 78.	6.2	40
66	Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors. Nuclear Medicine and Biology, 2014, 41, 749-757.	0.6	39
67	The Role of 89Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals. Journal of Nuclear Medicine, 2021, 62, 438-445.	5.0	39
68	A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice. EJNMMI Research, 2015, 5, 14.	2.5	38
69	Amyloid and its association with default network integrity in Alzheimer's disease. Human Brain Mapping, 2014, 35, 779-791.	3.6	37
70	(R)-[11C]PK11195 brain uptake as a biomarker of inflammation and antiepileptic drug resistance: Evaluation in a rat epilepsy model. Neuropharmacology, 2014, 85, 104-112.	4.1	37
71	Brain penetration of the histamine H3 receptor antagonists thioperamide and clobenpropit in rat and mouse, determined with ex vivo [125I]iodophenpropit binding. Brain Research, 1996, 743, 178-183.	2.2	36
72	Synthesis and biodistribution of [11C]R107474, a new radiolabeled Î±2-adrenoceptor antagonist. Bioorganic and Medicinal Chemistry, 2006, 14, 4526-4534.	3.0	35

#	Article	IF	Citations
73	The role of neuroimaging in Parkinson's disease. Journal of Neurochemistry, 2021, 159, 660-689.	3.9	35
74	A complete, multipurpose, low cost, fully automated and GMP compliant radiosynthesis system. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, S1052.	1.0	34
75	One-pot synthesis of [11C]ureas via triphenylphosphinimines. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 321-330.	1.0	34
76	Quantification of Dopamine Transporter Binding Using [18F]FP-β-CIT and Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1397-1406.	4.3	34
77	Promising potential of new generation translocator protein tracers providing enhanced contrast of arthritis imaging by positron emission tomography in a rat model of arthritis. Arthritis Research and Therapy, 2014, 16, R70.	3.5	32
78	Quantification of ^{18}F-Fluorocholine Kinetics in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 365-371.	5.0	32
79	Simplified Methods for Quantification of ^{18}F-DCFPyL Uptake in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1730-1735.	5.0	32
80	Fully automated high yield synthesis of (R)- and (S)-[11C]verapamil for measuring P-glycoprotein function with positron emission tomography. Journal of Labelled Compounds and Radiopharmaceuticals, 2002, 45, 1199-1207.	1.0	31
81	EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD). European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2175-2185.	6.4	31
82	In Vivo Imaging of Hypoxia in Atherosclerotic Plaques in Humans. JACC: Cardiovascular Imaging, 2015, 8, 1340-1341.	5.3	31
83	Evaluation of [18 F]VUF 5000 as a potential PET ligand for brain imaging of the histamine H 3 receptor. Bioorganic and Medicinal Chemistry, 1999, 7, 1761-1767.	3.0	30
84	Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLC. EJNMMI Research, 2016, 6, 10.	2.5	30
85	Pharmacological Evaluation of Novel Bioisosteres of an Adamantanyl Benzamide P2X$_7$ Receptor Antagonist. ACS Chemical Neuroscience, 2017, 8, 2374-2380.	3.5	30
86	Radiosynthesis and biodistribution of a histamine H3 receptor antagonist 4-[3-(4-piperidin-1-yl-but-1-ynyl)-[11C]benzyl]-morpholine: evaluation of a potential PET ligand. Nuclear Medicine and Biology, 2006, 33, 801-810.	0.6	29
87	Pediatric Microdose Study of [14C]Paracetamol to Study Drug Metabolism Using Accelerated Mass Spectrometry: Proof of Concept. Clinical Pharmacokinetics, 2014, 53, 1045-1051.	3.5	29
88	Development of carbon-11 labeled acryl amides for selective PET imaging of active tissue transglutaminase. Nuclear Medicine and Biology, 2016, 43, 232-242.	0.6	29
89	Evaluation of [^{18}F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood–brain barrier in rats: Kinetics, metabolism, and selectivity. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1286-1298.	4.3	29
90	Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2866-2878.	6.4	29

#	ARTICLE	IF	CITATIONS
91	[11C]phenytoin revisited: synthesis by [11C]CO carbonylation and first evaluation as a P-gp tracer in rats. EJNMMI Research, 2012, 2, 36.	2.5	28
92	Guidelines to PET measurements of the target occupancy in the brain for drug development. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2255-2262.	6.4	28
93	Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3165-3175.	6.4	28
94	Towards PET imaging of the dynamic phenotypes of microglia. Clinical and Experimental Immunology, 2021, 206, 282-300.	2.6	28
95	Tumour imaging by Positron Emission Tomography using fluorinase generated 5-[18F]fluoro-5-deoxyribose as a novel tracer. Nuclear Medicine and Biology, 2013, 40, 464-470.	0.6	27
96	Quantification of [11C]-meta-hydroxyephedrine uptake in human myocardium. EJNMMI Research, 2014, 4, 52.	2.5	27
97	Use of a Single [11]C-*Meta*-Hydroxyephedrine Scan for Assessing Flow–Innervation Mismatches in Patients with Ischemic Cardiomyopathy. Journal of Nuclear Medicine, 2015, 56, 1706-1711.	5.0	27
98	Altered GABA$_A$ Receptor Density and Unaltered Blood–Brain Barrier Transport in a Kainate Model of Epilepsy: An In Vivo Study Using ^{11}C-Flumazenil and PET. Journal of Nuclear Medicine, 2012, 53, 1974-1983.	5.0	26
99	Radiopharmaceuticals for assessing ABC transporters at the blood–brain barrier. Clinical Pharmacology and Therapeutics, 2015, 97, 362-371.	4.7	25
100	Peripheral metabolism of [18F]FDDNP and cerebral uptake of its labelled metabolites. Nuclear Medicine and Biology, 2008, 35, 869-874.	0.6	24
101	[11C]Sorafenib: Radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer. Nuclear Medicine and Biology, 2013, 40, 488-497.	0.6	24
102	Comparison of Simplified Parametric Methods for Visual Interpretation of ^{11}C-Pittsburgh Compound-B PET Images. Journal of Nuclear Medicine, 2014, 55, 1305-1307.	5.0	24
103	Residual solvent analysis by gas chromatography in radiopharmaceutical formulations containing up to 12% ethanol. Nuclear Medicine and Biology, 2006, 33, 935-938.	0.6	23
104	Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1523-1531.	6.4	23
105	Pediatric microdose and microtracer studies using ^{14}C in Europe. Clinical Pharmacology and Therapeutics, 2015, 98, 234-237.	4.7	23
106	Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood–Brain Barrier. Molecular Pharmaceutics, 2015, 12, 2265-2275.	4.6	23
107	Parametric Binding Images of the TSPO Ligand ^{18}F-DPA-714. Journal of Nuclear Medicine, 2016, 57, 1543-1547.	5.0	23
108	Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. Annals of Nuclear Medicine, 2018, 32, 236-238.	2.2	23

#	Article	IF	Citations
109	Fast and reliable generation of [^{18}F]triflyl fluoride, a gaseous [^{18}F]fluoride source. Chemical Communications, 2018, 54, 10179-10182.	4.1	23
110	[11C]quinidine and [11C]laniquidar PET imaging in a chronic rodent epilepsy model: Impact of epilepsy and drug-responsiveness. Nuclear Medicine and Biology, 2013, 40, 764-775.	0.6	22
111	The Dopamine Stabilizer (â^')-OSU6162 Occupies a Subpopulation of Striatal Dopamine D2/D3 Receptors: An [11C]Raclopride PET Study in Healthy Human Subjects. Neuropsychopharmacology, 2015, 40, 472-479.	5.4	22
112	Quantitative and Simplified Analysis of ^{11}C-Erlotinib Studies. Journal of Nuclear Medicine, 2016, 57, 861-866.	5.0	22
113	Novel molecular imaging ligands targeting matrix metalloproteinases 2 and 9 for imaging of unstable atherosclerotic plaques. PLoS ONE, 2017, 12, e0187767.	2.5	22
114	From Carbon-11-Labeled Amino Acids to Peptides in Positron Emission Tomography: the Synthesis and Clinical Application. Molecular Imaging and Biology, 2018, 20, 510-532.	2.6	22
115	Quantification of [^{18}F]florbetapir: A testâ€"retest tracer kinetic modelling study. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 2172-2180.	4.3	22
116	Parametric methods for [^{18}F]flortaucipir PET. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 365-373.	4.3	22
117	Carbon-11 Labeled Tracers for In Vivo Imaging of P-Glycoprotein Function: Kinetics, Advantages and Disadvantages. Current Topics in Medicinal Chemistry, 2010, 10, 1820-1833.	2.1	21
118	^{11}Câ€labeled and ^{18}Fâ€labeled PET ligands for subtypeâ€specific imaging of histamine receptors in the brain. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 120-129.	1.0	21
119	Microdosing of a Carbonâ€14 Labeled Protein in Healthy Volunteers Accurately Predicts Its Pharmacokinetics at Therapeutic Dosages. Clinical Pharmacology and Therapeutics, 2015, 98, 196-204.	4.7	21
120	Preclinical evaluation of [18F]PK-209, a new PET ligand for imaging the ion-channel site of NMDA receptors. Nuclear Medicine and Biology, 2015, 42, 205-212.	0.6	21
121	P-glycoprotein Function in the Rodent Brain Displays a Daily Rhythm, a Quantitative In Vivo PET Study. AAPS Journal, 2016, 18, 1524-1531.	4.4	21
122	PET and CSF amyloid-Î² status are differently predicted by patient features: information from discordant cases. Alzheimer's Research and Therapy, 2019, 11, 100.	6.2	21
123	Evaluation of Tracer Kinetic Models for Analysis of [18F]FDDNP Studies. Molecular Imaging and Biology, 2009, 11, 322-333.	2.6	20
124	Imaging of Fibrogenesis in Patients with Idiopathic Pulmonary Fibrosis with cis-4-[18F]-Fluoro-l-Proline PET. Molecular Imaging and Biology, 2009, 11, 123-127.	2.6	19
125	Absolute Quantification of [11C]docetaxel Kinetics in Lung Cancer Patients Using Positron Emission Tomography. Clinical Cancer Research, 2011, 17, 4814-4824.	7.0	19
126	Quantification of the novel *N*-methyl-d-aspartate receptor ligand [^{11}C]GMOM in man. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1111-1121.	4.3	19

#	Article	IF	Citations
127	Successful Use of [14C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug Metabolism. Clinical Pharmacokinetics, 2017, 56, 1185-1195.	3.5	19
128	A novel partial volume correction method for accurate quantification of [18F] flortaucipir in the hippocampus. EJNMMI Research, 2018, 8, 79.	2.5	19
129	Fully Automated ^{89}Zr Labeling and Purification of Antibodies. Journal of Nuclear Medicine, 2019, 60, 691-695.	5.0	19
130	Characterization of the Binding Site of the Histamine H3Receptor. 2. Synthesis, in Vitro Pharmacology, and QSAR of a Series of Monosubstituted Benzyl Analogues of Thioperamide. Journal of Medicinal Chemistry, 2000, 43, 1754-1761.	6.4	18
131	No Evidence for Additional Blood–Brain Barrier P-Glycoprotein Dysfunction in Alzheimer's Disease Patients with Microbleeds. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1468-1471.	4.3	18
132	[11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors. EJNMMI Research, 2013, 3, 19.	2.5	18
133	Model selection criteria for dynamic brain PET studies. EJNMMI Physics, 2017, 4, 30.	2.7	18
134	Radiosynthesis of[11C]docetaxel. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 763-777.	1.0	17
135	In vivo quantification of striatal dopamine D$_2$receptor occupancy by JNJ-37822681 using [^{11}C]raclopride and positron emission tomography. Journal of Psychopharmacology, 2012, 26, 1128-1135.	4.0	17
136	Structure–activity relationships of N-substituted 4-(trifluoromethoxy)benzamidines with affinity for GluN2B-containing NMDA receptors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 828-830.	2.2	17
137	Assessment of Simplified Methods to Measure ^{18}F-FLT Uptake Changes in EGFR-Mutated Non–Small Cell Lung Cancer Patients Undergoing EGFR Tyrosine Kinase Inhibitor Treatment. Journal of Nuclear Medicine, 2014, 55, 1417-1423.	5.0	17
138	Quantification of Dynamic ^{11}C-Phenytoin PET Studies. Journal of Nuclear Medicine, 2015, 56, 1372-1377.	5.0	17
139	In-vivo monitoring of anti-folate therapy in arthritic rats using [18F]fluoro-PEG-folate and positron emission tomography. Arthritis Research and Therapy, 2017, 19, 114.	3.5	17
140	Imaging and Methotrexate Response Monitoring of Systemic Inflammation in Arthritic Rats Employing the Macrophage PET Tracer [^{18}F]Fluoro-PEG-Folate. Contrast Media and Molecular Imaging, 2018, 2018, 1-10.	0.8	17
141	Imaging disease activity of rheumatoid arthritis by macrophage targeting using second generation translocator protein positron emission tomography tracers. PLoS ONE, 2019, 14, e0222844.	2.5	17
142	Synthesis of [^{18}F]Fluoroform with High Molar Activity. European Journal of Organic Chemistry, 2020, 2020, 1177-1185.	2.4	17
143	Synthesis and preclinical evaluation of [11C]D617, a metabolite of (R)-[11C]verapamil. Nuclear Medicine and Biology, 2012, 39, 530-539.	0.6	16
144	Polyfluorinated bis-styrylbenzenes as amyloid-β plaque binding ligands. Bioorganic and Medicinal Chemistry, 2014, 22, 2469-2481.	3.0	16

#	Article	IF	Citations
145	A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies. Alzheimer's and Dementia, 2019, 15, 1081-1103.	0.8	16
146	[18F]Flortaucipir PET Across Various *MAPT* Mutations in Presymptomatic and Symptomatic Carriers. Neurology, 2021, 97, e1017-e1030.	1.1	16
147	ReductiveN-alkylation of secondary amines with [2-11C]acetone. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 1075-1085.	1.0	15
148	Imaging of TKI–Target Interactions for Personalized Cancer Therapy. Clinical Pharmacology and Therapeutics, 2013, 93, 239-241.	4.7	15
149	Synthesis and preclinical evaluation of carbon-11 labelled N-((5-(4-fluoro-2-[11C]methoxyphenyl)pyridin-3-yl)methyl)cyclopentanamine as a PET tracer for NR2B subunit-containing NMDA receptors. Nuclear Medicine and Biology, 2014, 41, 670-680.	0.6	15
150	PET imaging of P2X7R in the experimental autoimmune encephalomyelitis model of multiple sclerosis using [11C]SMW139. Journal of Neuroinflammation, 2020, 17, 300.	7.2	15
151	Novel Thienopyrimidine-Based PET Tracers for P2Y$_{12}$ Receptor Imaging in the Brain. ACS Chemical Neuroscience, 2021, 12, 4465-4474.	3.5	15
152	Synthesis and biodistribution of [11C]R116301, a promising PET ligand for central NK1 receptors. Bioorganic and Medicinal Chemistry, 2005, 13, 1579-1586.	3.0	14
153	Synthesis ofN-(3-[18F]Fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl)nortropane ([18F]FP-β-CIT). Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 77-89.	1.0	14
154	3′-Sulfonylesters of 2,5′-anhydro-1-(2-deoxy-β-d-threo-pentofuranosyl)thymine as precursors for the synthesis of [18F]FLT: syntheses and radiofluorination trials. Nuclear Medicine and Biology, 2008, 35, 413-423.	0.6	14
155	Synthesis, structure activity relationship, radiolabeling and preclinical evaluation of high affinity ligands for the ion channel of the N-methyl-d-aspartate receptor as potential imaging probes for positron emission tomography. Bioorganic and Medicinal Chemistry, 2015, 23, 1189-1206.	3.0	14
156	Quantification of O-(2-[18F]fluoroethyl)-L-tyrosine kinetics in glioma. EJNMMI Research, 2018, 8, 72.	2.5	14
157	Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study. NeuroImage: Clinical, 2020, 28, 102504.	2.7	14
158	The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study. Clinical Pharmacology and Therapeutics, 2021, 109, 140-149.	4.7	14
159	Synthesis of 2-(1,1-dicyanopropen-2-yl)-6-(2-[18F]-fluoroethyl)-methylamino-naphthalene ([18F]FDDNP). Applied Radiation and Isotopes, 2008, 66, 203-207.	1.5	13
160	Pharmacokinetic modeling of a novel hypoxia PET tracer [18F]HX4 in patients with non-small cell lung cancer. EJNMMI Physics, 2016, 3, 30.	2.7	13
161	Multiparametric Analysis of the Relationship Between Tumor Hypoxia and Perfusion with [18F]F-Fluoroazomycin Arabinoside and [15O]O-H$_2$O PET. Journal of Nuclear Medicine, 2016, 57, 530-535.	5.0	13
162	Enantioselective synthesis of carbon-11 labeled l-alanine using phase transfer catalysis of Schiff bases. Tetrahedron, 2016, 72, 6551-6557.	1.9	13

#	Article	IF	Citations
163	A rapid and highly enantioselective C–[11]C bond formation of l-[^{11}C]phenylalanine via chiral phase-transfer catalysis. Organic and Biomolecular Chemistry, 2017, 15, 570-575.	2.8	13
164	Prophylactic and therapeutic activity of alkaline phosphatase in arthritic rats: single-agent effects of alkaline phosphatase and synergistic effects in combination with methotrexate. Translational Research, 2018, 199, 24-38.	5.0	13
165	Improved and semi-automated GMP-compliant radiosynthesis of [11C]docetaxel. Applied Radiation and Isotopes, 2008, 66, 1414-1418.	1.5	12
166	Reproducible Analysis of Rat Brain PET Studies Using an Additional [^{18}F]NaF Scan and an MR-Based ROI Template. International Journal of Molecular Imaging, 2012, 2012, 1-10.	1.3	12
167	Radiation Dose of the P-Glycoprotein Tracer ^{11}C-Laniquidar. Journal of Nuclear Medicine, 2013, 54, 2101-2103.	5.0	12
168	Parametric Methods for Quantification of 18F-FAZA Kinetics in Non–Small Cell Lung Cancer Patients. Journal of Nuclear Medicine, 2014, 55, 1772-1777.	5.0	12
169	Improved synthesis and application of [^{11}C]benzyl iodide in positron emission tomography radiotracer production. Journal of Labelled Compounds and Radiopharmaceuticals, 2015, 58, 342-348.	1.0	12
170	Genetically identical twins show comparable tau PET load and spatial distribution. Brain, 2022, 145, 3571-3581.	7.6	12
171	Two anti-angiogenic TKI-PET tracers, [11 C]axitinib and [11 C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents. Nuclear Medicine and Biology, 2016, 43, 612-624.	0.6	11
172	Strategies towards in vivo imaging of active transglutaminase type 2 using positron emission tomography. Amino Acids, 2017, 49, 585-595.	2.7	11
173	Stereoselective [11]C Labeling of a "Native" Tetrapeptide by Using Asymmetric Phase–Transfer Catalyzed Alkylation Reactions. European Journal of Organic Chemistry, 2017, 2017, 1019-1024.	2.4	11
174	Radiosynthesis and biodistribution of 123I-labeled antagonists of the histamine H3 receptor as potential SPECT ligands. Nuclear Medicine and Biology, 1999, 26, 651-659.	0.6	10
175	Radiosynthesis and preclinical evaluation of [11C]prucalopride as a potential agonist PET ligand for the 5-HT4 receptor. EJNMMI Research, 2013, 3, 24.	2.5	10
176	Synthesis, radiolabeling and evaluation of novel amine guanidine derivatives as potential positron emission tomography tracers for the ion channel of the N-methyl-d-aspartate receptor. European Journal of Medicinal Chemistry, 2016, 118, 143-160.	5.5	10
177	Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1221-1227.	5.0	10
178	Repeatability of parametric methods for [^{18}F]florbetapir imaging in Alzheimer's disease and healthy controls: A test–retest study. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 569-578.	4.3	10
179	BLZ945 derivatives for PET imaging of colony stimulating factor-1 receptors in the brain. Nuclear Medicine and Biology, 2021, 100-101, 44-51.	0.6	10
180	Simultaneous in vivo measurements of receptor density and affinity using [11C]flumazenil and positron emission tomography: Comparison of full saturation and steady state methods. NeuroImage, 2011, 57, 928-937.	4.2	9

#	ARTICLE	IF	CITATIONS
181	Radiosynthesis and biological evaluation of the M1 muscarinic acetylcholine receptor agonist ligand [^{11}C]AF150(S). Journal of Labelled Compounds and Radiopharmaceuticals, 2012, 55, 264-273.	1.0	9
182	Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237). Nuclear Medicine and Biology, 2016, 43, 63-72.	0.6	9
183	Myocardial denervation coincides with scar heterogeneity in ischemic cardiomyopathy: A PET and CMR study. Journal of Nuclear Cardiology, 2016, 23, 1480-1488.	2.1	9
184	Synthesis, radiolabeling and preclinical evaluation of a [11 C]GMOM derivative as PET radiotracer for the ion channel of the N-methyl-D-aspartate receptor. Nuclear Medicine and Biology, 2017, 51, 25-32.	0.6	9
185	Stereocontrolled [^{11}C]Alkylation of N-Terminal Glycine Schiff Bases To Obtain Dipeptides. European Journal of Organic Chemistry, 2017, 2017, 5592-5596.	2.4	9
186	First in human evaluation of [18F]PK-209, a PET ligand for the ion channel binding site of NMDA receptors. EJNMMI Research, 2018, 8, 69.	2.5	9
187	Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 7.	3.9	9
188	Application of advanced brain positron emission tomography–based molecular imaging for a biological framework in neurodegenerative proteinopathies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 327-332.	2.4	9
189	First Evaluation of [11C]R116301 as an In Vivo Tracer of NK1 Receptors in Man. Molecular Imaging and Biology, 2009, 11, 241-245.	2.6	8
190	Efficient Synthesis of ^{11}C-Acrylesters, ^{11}C-Acrylamides and Their Application in Michael Addition Reactions for PET Tracer Development. European Journal of Organic Chemistry, 2017, 2017, 5154-5162.	2.4	8
191	Synthesis and Evaluation of New Fluorine-18 Labeled Verapamil Analogs To Investigate the Function of P-Glycoprotein in the Blood–Brain Barrier. ACS Chemical Neuroscience, 2017, 8, 1925-1936.	3.5	8
192	Development of fluorine-18 labeled peptidic PET tracers for imaging active tissue transglutaminase. Nuclear Medicine and Biology, 2017, 44, 90-104.	0.6	8
193	Evaluation of the Novel PET Tracer [11C]HACH242 for Imaging the GluN2B NMDA Receptor in Non-Human Primates. Molecular Imaging and Biology, 2019, 21, 676-685.	2.6	8
194	Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?. Journal of Alzheimer's Disease, 2020, 73, 559-569.	2.6	8
195	Fluorine-18 labelled Ruppert–Prakash reagent ([^{18}F]Me$_3$SiCF$_3$) for the synthesis of ^{18}F-trifluoromethylated compounds. Chemical Communications, 2021, 57, 5286-5289.	4.1	8
196	Evaluation of carbon-11 labeled 5-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)nicotinamide as PET tracer for imaging of CSF-1R expression in the brain. Bioorganic and Medicinal Chemistry, 2021, 42, 116245.	3.0	8
197	Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy. Cancers, 2021, 13, 6088.	3.7	8
198	Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1951-1963.	6.4	8

#	Article	IF	Citations
199	Folate Receptor Beta for Macrophage Imaging in Rheumatoid Arthritis. Frontiers in Immunology, 2022, 13, 819163.	4.8	8
200	Synthesis,in vitro pharmacology and radiosynthesis ofN-(cis-4-fluoromethylcycloyhexyl)-4-(1(H)-imidazol-4-yl)piperidine-11-thiocarbonamide (VUF 5000), a potential PET ligand for the histamine H3 receptor. , 1999, 42, 293-307.		7
201	The binding characteristics and orientation of a novel radioligand with distinct properties at 5-HT3A and 5-HT3AB receptors. Neuropharmacology, 2014, 86, 378-388.	4.1	7
202	The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1190-8.	6.4	7
203	Improving metabolic stability of fluorine-18 labeled verapamil analogs. Nuclear Medicine and Biology, 2018, 64-65, 47-56.	0.6	7
204	Status of the 'consensus nomenclature rules in radiopharmaceutical sciences' initiative. Nuclear Medicine and Biology, 2019, 71, 19-22.	0.6	7
205	Development of [11C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenografts. Oncotarget, 2017, 8, 38337-38350.	1.8	7
206	In vivo imaging of TGFβ signalling components using positron emission tomography. Drug Discovery Today, 2019, 24, 2258-2272.	6.4	6
207	Design, Synthesis, Conjugation, and Reactivity of Novel *trans,trans*-1,5-Cyclooctadiene-Derived Bioorthogonal Linkers. Bioconjugate Chemistry, 2020, 31, 2201-2210.	3.6	6
208	Performance of nanoScan PET/CT and PET/MR for quantitative imaging of 18F and 89Zr as compared with ex vivo biodistribution in tumor-bearing mice. EJNMMI Research, 2021, 11, 57.	2.5	6
209	The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor. Pharmaceuticals, 2022, 15, 450.	3.8	6
210	Quantification of ^{11}C-Laniquidar Kinetics in the Brain. Journal of Nuclear Medicine, 2015, 56, 1730-1735.	5.0	5
211	Synthesis of [3‐*N*‐^{11}C‐methyl]temozolomide via *in situ* activation of 3‐*N*‐hydroxymethyl temozolomide and alkylation with [^{11}C]methyl iodide. Journal of Labelled Compounds and Radiopharmaceuticals, 2015, 58, 122-126.	1.0	5
212	Bis-pyridylethenyl benzene as novel backbone for amyloid-β binding compounds. Bioorganic and Medicinal Chemistry, 2016, 24, 6139-6148.	3.0	5
213	Open letter to journal editors on: International consensus radiochemistry nomenclature guidelines. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 402-404.	1.0	5
214	In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model. EJNMMI Research, 2018, 8, 39.	2.5	5
215	Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships. NeuroImage: Clinical, 2020, 25, 102113.	2.7	5
216	Grey zone amyloid burden affects memory function: the SCIENCe project. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 747-756.	6.4	5

#	Article	IF	Citations
217	Evaluating N –difluoromethyltriazolium triflate as a precursor for the synthesis of high molar activity [18 F]fluoroform. Journal of Labelled Compounds and Radiopharmaceuticals, 2021, 64, 466-476.	1.0	5
218	Quantification of the neurokinin 1 receptor ligand [11C]R116301. Nuclear Medicine Communications, 2011, 32, 896-902.	1.1	4
219	Subchronic treatment with phencyclidine in adolescence leads to impaired exploratory behavior in adult rats without altering social interaction or *N*–methyl–D–aspartate receptor binding levels. Journal of Neuroscience Research, 2014, 92, 1599-1607.	2.9	4
220	Comparison of In Vitro Assays in Selecting Radiotracers for In Vivo P-Glycoprotein PET Imaging. Pharmaceuticals, 2017, 10, 76.	3.8	4
221	Synthesis and preliminary preclinical evaluation of fluorine-18 labelled isatin-4-(4-methoxyphenyl)-3-thiosemicarbazone ([18F]4FIMPTC) as a novel PET tracer of P-glycoprotein expression. EJNMMI Radiopharmacy and Chemistry, 2018, 3, 11.	3.9	4
222	Synthesis and pet-studies of (R)-and (S)-[11C]verapamil for measuring PGP function in MDR1A(+/+)/B(+/+) and MDR1A(-/-)/B(-/-) mice. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, S313-S315.	1.0	3
223	Radiosynthesis and biodistribution of [^{11}C]R107474 as a potential pet ligand for central α_2–adrenoceptors. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, S427.	1.0	3
224	Impact of New Scatter Correction Strategies on High-Resolution Research Tomograph Brain PET Studies. Molecular Imaging and Biology, 2016, 18, 627-635.	2.6	3
225	Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. Clinical and Translational Imaging, 2019, 7, 61-63.	2.1	3
226	Binding characterization of N –(2–chloro–5–thiomethylphenyl)–N –²–(3–[3 H] 3 methoxy phenyl)–N –²–methylguanidine ([3 H] GMOM), a non–competitive N –methyl–D–aspartate (NMDA) receptor antagonist. Pharmacology Research and Perspectives, 2019, 7, e00458.	2.1	3
227	Novel application of [18F]DPA714 for visualizing the pulmonary inflammation process of SARS-CoV-2-infection in rhesus monkeys (Macaca mulatta). Nuclear Medicine and Biology, 2022, 112-113, 1-8.	0.6	3
228	Synthesis of radioligands for the histamine H3 receptor. Pharmacochemistry Library, 1998, , 159-174.	0.1	2
229	Radiosynthesis of 1–iodo–2–[^{11}C]methylpropane and 2–methyl–1–[^{11}C]propanol and its application for alkylation reactions and C–C bond formation. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 566-576.	1.0	2
230	Human Dosimetry of the *N*-Methyl-d-Aspartate Receptor Ligand ^{11}C-GMOM. Journal of Nuclear Medicine, 2017, 58, 1330-1333.	5.0	2
231	Parametric Methods for Dynamic 11C-Phenytoin PET Studies. Journal of Nuclear Medicine, 2017, 58, 479-483.	5.0	2
232	Tau pathology, relative cerebral flow and cognition in dementia with Lewy bodies. Alzheimer's and Dementia, 2020, 16, e041048.	0.8	2
233	Design, Synthesis, Radiosynthesis and Biological Evaluation of Fenretinide Analogues as Anticancer and Metabolic Syndrome–Preventive Agents. ChemMedChem, 2020, 15, 1579-1590.	3.2	2
234	Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies. Molecular Imaging and Biology, 2021, 23, 550-559.	2.6	2

#	Article	IF	Citations
235	Synthesis and evaluation of [18F]cinacalcet for the imaging of parathyroid hyperplasia. Nuclear Medicine and Biology, 2021, 102-103, 97-105.	0.6	2
236	Pretargeted PET Imaging with a TCO-Conjugated Anti-CD44v6 Chimeric mAb U36 and [^{89}Zr]Zr-DFO-PEG$_5$-Tz. Bioconjugate Chemistry, 2022, 33, 956-968.	3.6	2
237	Insights into imaging in drug discovery and development. Drug Discovery Today: Technologies, 2011, 8, e43-e44.	4.0	1
238	International Consensus Radiochemistry Nomenclature Guidelines. Radiochimica Acta, 2018, 106, 623-625.	1.2	1
239	Synthesis and Preclinical Evaluation of the First Carbon-11 Labeled PET Tracers Targeting Substance P$_{1–7}$. Molecular Pharmaceutics, 2018, 15, 4872-4883.	4.6	1
240	Comparison of analytical methods for antibody conjugates with application in nuclear imaging â€" Report from the trenches. Nuclear Medicine and Biology, 2021, 102-103, 24-33.	0.6	1
241	PET Imaging of Purinergic Receptors. , 2021, , 879-889.		1
242	Neuroinflammation: From Target Selection to Preclinical and Clinical Studies. , 2021, , 567-592.		1
243	Open letter to journal editors on: international consensus radiochemistry nomenclature guidelines. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 70-72.	1.0	1
244	O4â€03â€01: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease. Alzheimer's and Dementia, 2012, 8, P618.	0.8	0
245	Bengt LÃ¥ngstrÃ¶m-a pioneer in carbon-11 radiochemistry. Journal of Labelled Compounds and Radiopharmaceuticals, 2015, 58, 47-48.	1.0	0
246	ICâ€Pâ€196: Quantification of TAU Load Using [^{18}F]AVâ€1451 and PET. Alzheimer's and Dementia, 2016, 12, P141.	0.8	0
247	P4â€215: Quantification of Tau Load Using [^{18}F]AVâ€1451 and Pet. Alzheimer's and Dementia, 2016, 12, P1109.	0.8	0
248	[P4â€235]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER's PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, P1364.	0.8	0
249	[ICâ€Pâ€206]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER's PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, P150.	0.8	0
250	Open letter to journal editors on. Nuclear Medicine Communications, 2018, 39, 193-195.	1.1	0
251	Open letter to journal editors on: international consensus radiochemistry nomenclature guidelines. Journal of Radioanalytical and Nuclear Chemistry, 2018, 315, 443-445.	1.5	0
252	ICâ€Pâ€222: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P180.	0.8	0

#	Article	IF	Citations
253	P3â€438: PARAMETRIC IMAGING OF [^{18}F]FLORBETAPIR: A TESTâ€RETEST STUDY IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1281.	0.8	0
254	P2â€360: [^{18}F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P827.	0.8	0
255	Letter to the Editor: International Consensus Radiochemistry Nomenclature Guidelines. Current Radiopharmaceuticals, 2018, 11, 73-75.	0.8	0
256	Earlyâ€onset Alzheimerâ€™s disease is related to differential spatial patterns of tau pathology and cognitive impairment. Alzheimer's and Dementia, 2020, 16, e042041.	0.8	0
257	Regional tau pathology is associated with loss of synapses and reduced synaptic activity: A combined [18 F]flortaucipir, [11 C]UCBâ€ and magnetoencephalography study. Alzheimer's and Dementia, 2020, 16, e045806.	0.8	0
258	Regional distribution of tau pathology in cognitively unimpaired, genetically identical twins. Alzheimer's and Dementia, 2020, 16, e045876.	0.8	0
259	Synchronizing chemistry, quantum mechanics and radioactivity in a revolutionary renewed atom model. Part 1: the elements where Z is 1â€"10 (H, He, Li, Be, B, C, N, O, F, Ne). RSC Advances, 2021, 11, 27978-27991.	3.6	0
260	State of the art of radiochemistry for 11C and 18F PET tracers. , 2021, , .		0
261	PET Imaging of ABC Transporters in the BBB. , 2014, , 625-652.		0
262	Imaging Histamine Receptors Using PET and SPECT. , 2014, , 331-376.		0
263	Genetically identical twins are highly similar in levels and spatial distribution of tau pathology: A [^{18}F]flortaucipir PET study. Alzheimer's and Dementia, 2021, 17, .	0.8	0